↓ Skip to main content

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases

Overview of attention for article published in Radiation Oncology, February 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
Published in
Radiation Oncology, February 2016
DOI 10.1186/s13014-016-0608-8
Pubmed ID
Authors

Jonathan W. Lischalk, Ryan M. Malik, Sean P. Collins, Brian T. Collins, Ismael A. Matus, Eric D. Anderson

Abstract

Radiotherapy of central lung tumors carries a higher risk of treatment-related toxicity and local failure. In the era of aggressive oligometastic management the exploration of the proper dose-fractionation for metastatic central lung tumors is essential. Patients diagnosed with high-risk metastatic lesions of the central pulmonary tree comprised this single-institutional retrospective analysis. "High-risk" central pulmonary lesions were defined as those with abutment and/or invasion of the mainstem bronchus. All patients were treated using the CyberKnife SBRT system in 5 fractions to a total dose of 35 or 40 Gy. Twenty patients were treated from 2008 to 2011 at Georgetown University Hospital. At a median follow up of 19 months, 1-year Kaplan-Meier local control and overall survival was 70 and 75 %, respectively. Late grade 2 or higher atelectasis was the most common treatment-related toxicity and was significantly associated with maximum dose to the mainstem bronchus. Gross endobronchial involvement was associated with significantly lower overall survival. Five-fraction SBRT to a total dose of 35 or 40 Gy appears to be a safe and effective management strategy for high-risk central pulmonary metastatic lesions, though care should be taken to limit the maximum point dose to the mainstem bronchus.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Other 8 16%
Researcher 8 16%
Student > Master 7 14%
Student > Postgraduate 5 10%
Student > Bachelor 4 8%
Other 8 16%
Unknown 11 22%
Readers by discipline Count As %
Medicine and Dentistry 27 53%
Physics and Astronomy 3 6%
Nursing and Health Professions 2 4%
Psychology 1 2%
Chemistry 1 2%
Other 1 2%
Unknown 16 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2022.
All research outputs
#14,942,462
of 24,187,594 outputs
Outputs from Radiation Oncology
#774
of 2,077 outputs
Outputs of similar age
#155,434
of 302,159 outputs
Outputs of similar age from Radiation Oncology
#13
of 52 outputs
Altmetric has tracked 24,187,594 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,077 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,159 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.